title: Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?
authors.affiliation: Department of Paediatric Respiratory Medicine, National Children's Hospital, Dublin, Ireland.
authors.forename: Basil
authors.initials: B
authors.lastname: Elnazir
authors.forename: Oluwole
authors.initials: O
authors.lastname: Oni
authors.forename: Taha
authors.initials: T
authors.lastname: Hassan
authors.forename: Peter
authors.initials: P
authors.lastname: Greally
authors.forename: Bosco
authors.initials: B
authors.lastname: Paes
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000821:virology*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab